Cargando…

Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients

Transforming growth factor beta (TGF-β) is a highly pleiotropic cytokine that has broad anti-inflammatory and immunosuppressive effects. In patients with systemic lupus erythematosus (SLE), the immunosuppressive effect of TGF-β1 is thought to be dysfunctional. In the present work, we aimed to study...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Bernal, Fuensanta, Quevedo-Abeledo, Juan Carlos, García-González, María, Fernández-Cladera, Yolanda, González-Rivero, Agustín F., de Vera-González, Antonia, Martín-González, Candelaria, González-Gay, Miguel Á., Ferraz-Amaro, Iván
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855909/
https://www.ncbi.nlm.nih.gov/pubmed/36671458
http://dx.doi.org/10.3390/biom13010073
_version_ 1784873491379519488
author Gómez-Bernal, Fuensanta
Quevedo-Abeledo, Juan Carlos
García-González, María
Fernández-Cladera, Yolanda
González-Rivero, Agustín F.
de Vera-González, Antonia
Martín-González, Candelaria
González-Gay, Miguel Á.
Ferraz-Amaro, Iván
author_facet Gómez-Bernal, Fuensanta
Quevedo-Abeledo, Juan Carlos
García-González, María
Fernández-Cladera, Yolanda
González-Rivero, Agustín F.
de Vera-González, Antonia
Martín-González, Candelaria
González-Gay, Miguel Á.
Ferraz-Amaro, Iván
author_sort Gómez-Bernal, Fuensanta
collection PubMed
description Transforming growth factor beta (TGF-β) is a highly pleiotropic cytokine that has broad anti-inflammatory and immunosuppressive effects. In patients with systemic lupus erythematosus (SLE), the immunosuppressive effect of TGF-β1 is thought to be dysfunctional. In the present work, we aimed to study the relationship between the serum levels of TGF-β1 with the characteristics of the disease as well as with the patterns of activity, damage, or severity of the disease. Two hundred and eighty-four patients with well-characterized SLE were recruited. The serum levels of TGF-β1 were assessed. A multivariable linear regression analysis was performed to analyze the relation of disease characteristics to TGF-β1. The Katz severity index (beta coefficient 179 [95% confidence interval 7–350] pg/mL, p = 0.041) and SLEDAI activity index (beta coefficient 96 [95% CI 20–171] pg/mL, p = 0.014) were associated with higher serum levels of TGF-β1 after the multivariable analysis. When the disease-specific features were studied, ocular and cardiovascular manifestations were positively associated with serum TGF-β1 levels. In contrast, gastrointestinal and musculoskeletal involvements were associated with lower levels of circulating TGF-β1. Among patients with SLE, the serum levels of TGF-β1 were highly associated with disease-related manifestations.
format Online
Article
Text
id pubmed-9855909
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98559092023-01-21 Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients Gómez-Bernal, Fuensanta Quevedo-Abeledo, Juan Carlos García-González, María Fernández-Cladera, Yolanda González-Rivero, Agustín F. de Vera-González, Antonia Martín-González, Candelaria González-Gay, Miguel Á. Ferraz-Amaro, Iván Biomolecules Article Transforming growth factor beta (TGF-β) is a highly pleiotropic cytokine that has broad anti-inflammatory and immunosuppressive effects. In patients with systemic lupus erythematosus (SLE), the immunosuppressive effect of TGF-β1 is thought to be dysfunctional. In the present work, we aimed to study the relationship between the serum levels of TGF-β1 with the characteristics of the disease as well as with the patterns of activity, damage, or severity of the disease. Two hundred and eighty-four patients with well-characterized SLE were recruited. The serum levels of TGF-β1 were assessed. A multivariable linear regression analysis was performed to analyze the relation of disease characteristics to TGF-β1. The Katz severity index (beta coefficient 179 [95% confidence interval 7–350] pg/mL, p = 0.041) and SLEDAI activity index (beta coefficient 96 [95% CI 20–171] pg/mL, p = 0.014) were associated with higher serum levels of TGF-β1 after the multivariable analysis. When the disease-specific features were studied, ocular and cardiovascular manifestations were positively associated with serum TGF-β1 levels. In contrast, gastrointestinal and musculoskeletal involvements were associated with lower levels of circulating TGF-β1. Among patients with SLE, the serum levels of TGF-β1 were highly associated with disease-related manifestations. MDPI 2022-12-29 /pmc/articles/PMC9855909/ /pubmed/36671458 http://dx.doi.org/10.3390/biom13010073 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gómez-Bernal, Fuensanta
Quevedo-Abeledo, Juan Carlos
García-González, María
Fernández-Cladera, Yolanda
González-Rivero, Agustín F.
de Vera-González, Antonia
Martín-González, Candelaria
González-Gay, Miguel Á.
Ferraz-Amaro, Iván
Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients
title Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients
title_full Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients
title_fullStr Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients
title_full_unstemmed Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients
title_short Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients
title_sort serum levels of transforming growth factor beta 1 in systemic lupus erythematosus patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855909/
https://www.ncbi.nlm.nih.gov/pubmed/36671458
http://dx.doi.org/10.3390/biom13010073
work_keys_str_mv AT gomezbernalfuensanta serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT quevedoabeledojuancarlos serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT garciagonzalezmaria serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT fernandezcladerayolanda serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT gonzalezriveroagustinf serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT deveragonzalezantonia serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT martingonzalezcandelaria serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT gonzalezgaymiguela serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients
AT ferrazamaroivan serumlevelsoftransforminggrowthfactorbeta1insystemiclupuserythematosuspatients